Shrinidhi Nathany: Why the Theriome Matters More Than We Think
Shrinidhi Nathany, Consultant Molecular Hematology and Oncology at Fortis Memorial, posted on LinkedIn:
“Sunday learning with the boss Dr. Rahul Bhargava
After a break back with a bang.. with more new concepts
As i started a thread on theriome, i will continue that today
Why the Theriome Matters More Than We Think
We often ask why patients with the same diagnosis and similar mutations have very different outcomes.
The answer often lies in the theriome.
The theriome influences how aggressively a tumour behaves, how it escapes the immune system and how it responds or fails to respond to therapy. In hematologic malignancies, the bone marrow and lymphoid niche can actively protect malignant cells from chemotherapy and targeted drugs.
This is why genomics alone is sometimes not enough. To truly understand cancer behaviour, we must also understand the ecosystem in which the cancer lives.”
Stay informed with Hemostasis Today.
-
Jan 31, 2026, 16:35IV Thrombolysis Does Not Improve Vision in Acute CRAO: Ahmed Koriesh on TenCRAOS Study
-
Jan 31, 2026, 16:24Joyce John Chalakkal: The Dangerous Area of The Face….
-
Jan 31, 2026, 16:04Rayya Saadiq Reflects On Qatar Health Congress 2026
-
Jan 31, 2026, 15:12Amar Raval on Oral Thin Film Drug Delivery Systems for Thrombosis Therapy
-
Jan 31, 2026, 14:40Heghine Khachatryan on WFH’s Call to Advance Health Equity for People with Bleeding Disorders
-
Jan 31, 2026, 14:10Emilia Arturo: Snake Venom, Clotting, and CryoEM!
-
Jan 31, 2026, 08:13Ming Y Lim On The Value of National Mentorship
-
Jan 31, 2026, 06:37Christian Schulze Presents The Post-Hoc Analysis of the DanGer Shock Trial
-
Jan 31, 2026, 06:27Negative Trials Matter: Anne Hege Aamodt Shares The TenCRAOS Trial